Introduction
Despite the use of antibiotics pneumococcal infections continue to cause illness and death throughout the world.1 2 Patients who do not have spleens are particularly at risk3 and many clinical trials have assessed the efficacy of polyvalent pneumococcal vaccines in these patients. Some studies have shown the effectiveness of vaccination in affording protective concentrations of specific antibodies,4 while others have shown a limited serological response.8 9 Experimentally the cellular immune events that occur after immunisation with pneumococcal capsular polysaccharide (PCP) depend on the spleen for the response to the T cell independent antigen." 11 We have investigated at different intervals after vaccination in vitro IgM and IgG anti-PCP synthesis by peripheral blood lymphocytes in five splenectomised and five normal subjects to see if the same applies in man.
Patients and methods
Five splenectomised men (mean age 37-4 (SE 2-0) years, range [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] and five healthy male volunteers (mean age 33-0 (SE 2-0) years, range 28-39) consented to receive a subcutaneous injection of 0-5 ml polyvalent PCP vaccine (Pneumovax). At the same time they were given a booster intramuscular injection of 20 Lf ( until use. PCP was covalently bound to poly-L-lysine (molecular weight 30 000-70 000; Sigma) using cyanuric chloride as the coupling agent.'" A 50 M1 sample of a stock solution (50 mgl1) of each PCP or of affinity purified goat antihuman IgM or antihuman IgG antibody (100 mg/1) in phosphate buffered saline was added to the inner wells of microtitre plates and incubated overnight at room temperature in a humidified chamber. The next day each well was washed three times with 10,, bovine serum albumin in phosphate buffered saline. A 500 solution was then added and four hours later the microtitre plates were again washed three times. Plates so prepared were stored at 4 C until used. PCP and for total IgM and IgG were calculated in reference to these standard curves. Titres below 1 0 jug/l were assigned a value of 1-0 Lg, 1 for calculation.8 All samples were run in duplicate at a single time to reduce day to day variations. A suitable dilution of control serum was run in all the microtitre plates to check plate to plate variations that were consistently less than 100,. The specificity of the radioimmunoassays for human IgM and IgG anti-type 2 and anti-type 25 PCP was confirmed by complete inhibition after adding, in the first incubation, the appropriate PCP (500 ng) in soluble form. No binding comnpetition was seen when the other PCP or an unrelated antigen (tetanus toxoid; 500 ng) was added. Student's t test for unpaired data was used to assess differences between groups. All values are reported as means and SE.
Results
Before immunisation the Be cell fractions from splenectomised and normal subjects did not synthesise detectable quantities of IgG anti-PCP (figure). Seven days after immunisation the appearance of cells capable of secreting IgG anti-PCP, without T cell or mitogen requirement, was detected in both groups of subjects (figure). Since the range of IgG anti-PCP values was wide, differences were not shown between the two groups. The ability to synthesise IgG anti-PCP disappeared 21 days after vaccination. Synthesis of polyclonal IgG by unstimulated Be cells paralleled that of specific antibodies, since it was low before vaccination, increased at seven days, and returned to baseline at 21 days (figure). High concentrations of total IgG at seven days were due to the presence of B cells spontaneously secreting antibodies against the 14 valent pneumococcal vaccine. Over the same time an analogous synthesis ofIgM anti-PCP by unstimulated Be cells could not be detected and changes in the production of polyclonalIgM were not observed.
Twenty one days after immunisation significant differences between splenectomised and normal subjects were detected in the synthesis of IgM and IgG anti-type 2 and anti-type 25 PCP and of polyclonal IgM by mitogen stimulated lymphocyte cultures (tables I and II).
Polyclonal stimulation of reconstituted Be and Te cell fractions from splenectomised subjects did not induce secretion of measurable amounts of specificIgM or IgG antibodies, and irradiation of T lymphocytes resulted in low amounts of specific antibodies in a minority of patients. In addition, the production of polyclonalIgM was significantly impaired in mitogen stimulated cultures, and this defect was not abolished by irradiation of T cells. This reduced biosynthesis was consistently found whenever cells were activated with pokeweed mitogen. In all but one of the normal subjects pokeweed mitogen stimulated the secretion of specific IgM and IgG antibodies and T cell irradiation produced a conspicuous increase in titre of
IgM and IgG anti-PCP (tables I and II).

Discussion
The central role of the spleen in the body's immune response is exemplified by the increased risk of serious pyogenic infections in people without a spleen or with a non-functioning spleen. After in vivo immunisation with pneumococcal vaccine two phases in the immune response may be distinguished. The first is characterised by the appearance in the circulation of B cells secreting antigen specific antibodies, and the second by the presence of cells that secrete antigen specific antibodies only after polyclonal stimulation. ' in both splenectomised and normal subjects, while the second is detectable only in subjects with a functional spleen. At the same time a defect in the mitogen dependent polyclonal IgM antibody response may be shown in splenectomised patients. The transient appearance of such B cells after antigenic stimulation has been reported both in animals and in man. In animals antigen stimulated lymph nodes release into the efferent lymph and circulation lymphocytes secreting antigen specific antibodies. 16 Similarly B cells capable of synthesising antigen specific antibodies of IgG class in the absence of T cells and mitogen are present in the circulation of normal people from five days until 14 days after immunisation. '5 In mice the spleen is the primary site of formation of antibody after intraperitoneal immunisation with PCPl7 and the response synthesise anti-PCP antibodies, and synthesis of polyclonal IgM on stimulation with pokeweed mitogen is defective.
Hence it seems that in the early phase of the immune response the lymph nodes can replace the spleen in releasing cells spontaneously secreting antigen specific IgG antibodies. In the second phase the spleen is the main organ responsible for synthesis of anti-PCP antibodies and may contribute to the particular sensitivity of splenectomised subjects to pneumococcal infections. 2 Symptoms are never severe, and the neutrophil count quickly returns to normal once treatment is stopped. The basic pathogenic mechanism of the complication is not fully understood, but most reports postulate either a toxic effect or dose related damage3 7; an immunologically mediated mechanism has rarely been implicated '8 We report 13 patients who developed neutropenia after receiving intravenous or oral 3 lactamines. Leucoagglutinins were detected in eight out of nine patients tested. Table I summarises the 13 cases of neutropenia, which occurred during treatment with penicillin, oxacillin, amoxycillin, ampicillin, cefoperazone, cefotaxime, and ceftazidime. These : lactamines were administered either intravenously (10 cases) or by mouth (three cases) at a dose of 40-250 mg/kg/24 hours for severe sepsis. None of the patients had a history of allergy to penicillin. Other medications administered concomitantly varied, apart from an associated aminoglucoside (streptomycin, gentamicin, or amikacin). We excluded these as offending agents, since they were continued during the episode of leucopenia. In case 10 neutropenia was noted for the first time after oxacillin. Recovery was rapid after withdrawal of this drug, and the patient was given cephazolin. The neutrophil count fell again (to 88 x 106/1) and rapidly returned to normal once the drug was stopped.
Patients
Neutropenia was observed as early as day 8 after starting treatment in one patient, the longest latent period being 27 days. The mean time of onset after starting treatment was 19 days. Neutrophil counts ranged from 24 to 1885 x 101,1. Total white cell count was less than 3300 x 106/1 in all but one patient, in whom there was a dissociation between absolute neutrophil count (80 1061/) and leucocyte count (8000 106/1). There was no depression in red blood cell series.
Associated eosinophilia ( 400 >. 1071/I) was observed in six patients, thrombocytopenia in one, and blood myelocytosis in two. A transient generalised rash occurred in one patient and fever in three. Renal and hepatic function remained normal in all patients. The neutrophil count returned to normal within one to six days after stopping the ,B lactamines alone.
One patient (case 13) consented to receive a low dose of the same 3 lactamine (amoxycillin 500 mg by mouth) after her white cell count had returned to normal. This patient experienced a recurrence of the leucopenia, beginning within the next 24 hours. The bone marrow was examined in six patients. The results showed
